Neoadjuvant Chemotherapy in Elderly Breast Cancer Patients

Primary Indications for Neoadjuvant Chemotherapy

The American Society of Clinical Oncology recommends neoadjuvant chemotherapy for locally advanced breast cancer requiring tumor downstaging to achieve operability, with treatment decisions based on biological age and geriatric assessment rather than chronological age alone 1, 2, 3
The European Society for Medical Oncology suggests that large operable cancers (>2 cm) may benefit from neoadjuvant chemotherapy to enable breast-conserving surgery, with a goal of maximizing pathologic complete response (pCR) rates 1, 3, 4
The National Comprehensive Cancer Network recommends neoadjuvant chemotherapy for triple-negative breast cancer, as these tumors demonstrate higher pCR rates with neoadjuvant treatment, particularly when platinum compounds (carboplatin) are added for patients with BRCA1/2 mutations 1, 3
The American College of Surgeons advises that HER2-positive disease requires neoadjuvant trastuzumab combined with taxanes to increase pCR probability, with monitoring of cardiac function periodically (every 3-4 months) during trastuzumab therapy 1, 3, 4

The International Society of Geriatric Oncology recommends performing comprehensive geriatric assessment to categorize patients as "fit" versus "frail" before finalizing treatment decisions, evaluating comorbidities, functional status, cardiac function (LVEF), and renal function (creatinine clearance) 2, 3, 5, 6
The European Society of Breast Cancer Specialists suggests that fit elderly patients should receive identical treatments to younger counterparts with full drug doses whenever feasible, using the same neoadjuvant chemotherapy regimens as in younger patients—sequential anthracyclines and taxanes remain the standard 1, 3, 4
The National Institute on Aging recommends considering less aggressive regimens for frail elderly patients, though evidence for their efficacy compared to standard chemotherapy remains limited, with single-agent pegylated liposomal doxorubicin or metronomic cyclophosphamide plus methotrexate as feasible alternatives 1, 4

The American Geriatrics Society advises against withholding appropriate neoadjuvant chemotherapy based solely on chronological age, as elderly patients derive similar disease-free and overall survival benefits compared to younger patients, though they face increased risk of side effects and treatment-related mortality 1, 2, 3, 5, 6
The European Society for Medical Oncology recommends calculating creatinine clearance to assess renal function and adjust doses to reduce systemic toxicity, with monitoring of cardiac function periodically (every 3-4 months) during trastuzumab therapy 5, 8

The American Society of Clinical Oncology notes that all planned chemotherapy should be delivered preoperatively without dividing into preoperative and postoperative periods, regardless of tumor response magnitude, to increase the probability of achieving pCR, which is a proven prognostic factor for good outcomes 1, 4